药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
3,7,11,15-tetramethyl-hexadecan-1-ol
Rozrolimupab
The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
CR002
The risk or severity of adverse effects can be increased when CR002 is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Bavituximab
The risk or severity of adverse effects can be increased when Bavituximab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Fontolizumab
The risk or severity of adverse effects can be increased when Fontolizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Matuzumab
The risk or severity of adverse effects can be increased when Matuzumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Labetuzumab
The risk or severity of adverse effects can be increased when Labetuzumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Adecatumumab
The risk or severity of adverse effects can be increased when Adecatumumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
IGN311
The risk or severity of adverse effects can be increased when IGN311 is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Oregovomab
The risk or severity of adverse effects can be increased when Oregovomab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Bectumomab
The risk or severity of adverse effects can be increased when Bectumomab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Epratuzumab
The risk or severity of adverse effects can be increased when Epratuzumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Afelimomab
The risk or severity of adverse effects can be increased when Afelimomab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Pexelizumab
The risk or severity of adverse effects can be increased when Pexelizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Galiximab
The risk or severity of adverse effects can be increased when Galiximab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Dexniguldipine
The serum concentration of Belantamab mafodotin can be increased when it is combined with Dexniguldipine.
3,7,11,15-tetramethyl-hexadecan-1-ol
Brefeldin A
The serum concentration of Belantamab mafodotin can be increased when it is combined with Brefeldin A.
3,7,11,15-tetramethyl-hexadecan-1-ol
Formononetin
Formononetin may increase the thrombogenic activities of Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Biochanin A
Biochanin A may increase the thrombogenic activities of Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Moxestrol
Moxestrol may increase the thrombogenic activities of Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Epimestrol
Epimestrol may increase the thrombogenic activities of Belantamab mafodotin.